David Kirn

David H.
Kirn was the founder of SillaJen Biotherapeutics, Inc., founded in 2006, where the title held was President & Chief Medical Officer in 2012.
Dr. Kirn is the founder of 4D Molecular Therapeutics, Inc., founded in 2013, holding the titles of President, Chief Executive Officer & Director starting in 2026.
Dr. Kirn is also the founder of Ignite Immunotherapy, Inc...
Dr. Kirn is Chief Executive Officer at ReIGNITE Therapeutics, Inc. Dr. Kirn is Director at Coagulant Therapeutics, Inc. Dr. Kirn is Professor at the University of Oxford.
Former positions include Principal at Warner-Lambert Co., Principal at Onyx Pharmaceuticals, Inc. in 2009, Member at Harvard University, Faculty Member at The University of California, San Francisco, Advisor at National Institutes of Health, Principal at IP2IPO Innovations Ltd., and Faculty Member at Specialist Diabetes Research & Treatment Centre LLC.
Education includes an undergraduate degree from the University of California, Berkeley in 1985 and a doctorate from The University of California, San Francisco in 1989.